Condition: Acute Myeloid Leukemia · Sponsor: AbbVie
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo standard induction therapy, the current standard of care. This study will assess the change in disease activity and adverse events in adult participants with acute myeloid leukemia (AML) being treated with of the combination of azacitidine and venetoclax, in India. The combination of azacitidine and venetoclax is being evaluated in the treatment of acute myeloid leukemia (AML). Participants will receive azacitidine with increasing doses of venetoclax. Around 40 adult participants with a diagnosis of AML will be enrolled in the study at approximately 15 sites in India. Participants will receive venetoclax oral tablets once daily in increasing doses until the study dose is achieved. Then ventoclax oral tablets will continue once daily thereafter. Azacitidine will be given by subcutaneous (SC) or intravenous (IV) injection on Days 1-7 of each cycle. The total study duration is approximately 29 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Fortis Memorial Research Institute /ID# 268697 | Gurgaon, Haryana, India | Recruiting |
| Mazumdar Shaw Medical Center /ID# 270677 | Bengaluru, Karnataka, India | Recruiting |
| Regional Cancer Centre /ID# 268785 | Thiruvananthapuram, Kerala, India | Recruiting |
| LMMF's Deenanath Mangeshkar Hospital & Research Center /ID# 268781 | Pune, Maharashtra, India | Recruiting |
| Sahyadri Super Speciality Hospital /ID# 272074 | Pune, Maharashtra, India | Recruiting |
| All India Institute Of Medical Sciences - New Delhi /ID# 268357 | New Delhi, National Capital Territory of Delhi, India | Recruiting |
| Rajiv Gandhi Cancer Institute And Research Centre /ID# 268293 | New Delhi, National Capital Territory of Delhi, India | Recruiting |
| All India Institute Of Medical Sciences - Bhubaneswar /ID# 274879 | Bhubaneswar, Odisha, India | Recruiting |
| Apollo Cancer Centre /ID# 268780 | Chennai, Tamil Nadu, India | Recruiting |
| Cancer Institute (Wia) /ID# 268695 | Chennai, Tamil Nadu, India | Recruiting |
| Basavatarakam Indo American Cancer Hospital & Research Institute /ID# 268692 | Hyderabad, Telangana, India | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07044687